...
首页> 外文期刊>Iranian Journal of Neurology >Effects of pyridoxine supplementation on severity, frequency and duration of migraine attacks in migraine patients with aura: A double-blind randomized clinical trial study in Iran
【24h】

Effects of pyridoxine supplementation on severity, frequency and duration of migraine attacks in migraine patients with aura: A double-blind randomized clinical trial study in Iran

机译:吡ido醇对偏头痛先兆患者偏头痛发作的严重程度,频率和持续时间的影响:伊朗的一项双盲随机临床试验研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Migraine is a chronic disease that affects nearly 6% of men and 18% of women worldwide. There are various drugs, which can successfully decrease migraine symptoms and frequency of migraine attacks, but these drugs usually are expensive. Hence, this study aimed to assess the effects of pyridoxine supplementation on severity, frequency and duration of migraine attacks as well as headache diary results (HDR).Methods: This double-blind randomized clinical trial study was conducted on 66 patients with migraine with aura (MA) in Khorshid and Emam Mosa Sadr clinics of Isfahan University of Medical Sciences, Iran, in 2013. Patients were randomly allocated to receive either pyridoxine supplements (80 mg pyridoxine per day) or placebo. Severity, frequency and duration of migraine attacks and HDR were measured at baseline and at the end of the study.Results: Mean age of patients was 34.24 ± 9.44 years old. Pyridoxine supplementation led to a significant decrease in headache severity (?2.20 ± 1.70 compared with ?1 ± 1.50; P = 0.007), attacks duration (?8.30 ± 12.60 compared with ?1.70 ± 9.60; P = 0.030) and HDR (?89.70 ± 134.60 compared with ?6.10 ± 155.50; P = 0.040) compared with placebo, but was not effective on the frequency of migraine attacks (?2.30 ± 4 compared with ?1.20 ± 7.80; P = 0.510).Conclusion: Pyridoxine supplementation in patients with MA was effective on headache severity, attacks duration and HDR, but did not affect the frequency of migraine attacks.Key Words: Migraine with Aura, Pyridoxine, Headache, Iran
机译:背景:偏头痛是一种慢性病,影响了全世界近6%的男性和18%的女性。有多种药物可以成功减轻偏头痛症状和偏头痛发作频率,但是这些药物通常很昂贵。因此,本研究旨在评估补充吡ido醇对偏头痛发作的严重程度,频率和持续时间以及头痛日记结果(HDR)的影响。方法:这项双盲随机临床试验研究是针对66例先兆性偏头痛患者进行的。 (MA)于2013年在伊朗伊斯法罕医科大学的Khorshid和Emam Mosa Sadr诊所接受治疗。患者被随机分配接受吡ido醇补充剂(每天80 mg吡ido醇)或安慰剂。在基线和研究结束时测量偏头痛发作和HDR的严重程度,频率和持续时间。结果:患者的平均年龄为34.24±9.44岁。补充吡ox醇可显着降低头痛的严重程度(与?1±1.50相比,?2.20±1.70; P = 0.007),发作持续时间(与?1.70±9.60相比,?8.30±12.60; P = 0.030)和HDR(?89.70)与安慰剂相比,±134.60±6.10±155.50; P = 0.040),但对偏头痛发作的频率无效(β2.30±4较±1.20±7.80; P = 0.510)。结论:患者补充吡P醇MA可以有效改善头痛的严重程度,发作时间和HDR,但不影响偏头痛发作的频率。关键词:先兆性偏头痛,吡rid醇,头痛,伊朗

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号